Mengyun Li
Suzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
BiRD Regimen Followed by Anti-BCMA CAR-T Cell Immunotherapy as First-Line Therapy for Newly Diagnosed Multiple Myeloma: A Prospective, Single-Arm, Phase 2 Trial.
Journal: American journal of hematology
Published: December 27, 2025
Comparative efficacy and long-term survival of CD19/22 versus CD19 CAR-T immunotherapy in Relapsed/Refractory B-ALL with TP53 alterations.
Journal: Journal of translational medicine
Published: December 07, 2025
Effective Management of Carbapenem-Resistant Enterobacterales Bloodstream Infection with Organ Dissemination in Prolonged Severe Agranulocytosis Patients with Hematological Malignancy Through Combination Therapies Including Eravacycline.
Journal: Infectious diseases and therapy
Published: June 12, 2025
Tandem CD19/CD22 CAR T-Cell Therapy as First-Line Treatment for Adult Patients With High-Risk Philadelphia Chromosome Negative B-Cell Acute Lymphoblastic Leukemia.
Journal: American journal of hematology
Published: February 17, 2025
Decitabine consolidation after CD19/CD22 CAR-T therapy as a novel maintenance treatment significantly improves survival outcomes in relapsed/refractory B-ALL patients.
Journal: Leukemia research
Published: May 25, 2024
Successful treatment of a B/T MPAL patient by chemo-free treatment with venetoclax, azacitidine, and blinatumomab.
Journal: Annals of hematology
Published: December 18, 2023
Chidamide combined with a modified Bu-Cy conditioning regimen improves survival in patients with T-cell acute lymphoblastic leukemia/lymphoma undergoing allogeneic hematopoietic stem cell transplantation.
Journal: Annals of hematology
Published: December 12, 2023
Case report: Rare persistent complete donor chimerism and GVHD following micro-transplantation from HLA haplotype homozygous donors.
Journal: Frontiers in immunology
Published: July 28, 2022
CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed/refractory acute myeloid leukemia.
Journal: Experimental hematology & oncology
Published: June 27, 2022
Overall survival benefits provided by lenalidomide maintenance after chimeric antigen receptor T cell therapy in patients with refractory/relapsed diffuse large B-cell lymphoma.
Journal: Annals of translational medicine
Published: December 07, 2021
Venetoclax and decitabine in refractory TP53-mutated early T-cell precursor acute lymphoblastic leukemia.
Journal: Annals of hematology
Published: December 21, 2020
Efficacy of venetoclax in combination with azacitidine followed by haploidentical transplantation in refractory acute myeloid leukaemia and mixed phenotype acute leukaemia.
Journal: British journal of haematology
Published: December 16, 2019
Last Updated: 09/26/2026